Drug Database
PR

pregabalin (pregabalin, YuHan / YHD 1119 / YHD1119)

✓ Approved

YuHan · CACNA2D1 · 小分子

什么是 pregabalin?

pregabalin 是一种小分子,由YuHan研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名pregabalin, YuHan, YHD 1119, YHD1119
公司YuHan
药物类别小分子
分子靶点CACNA2D1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

pregabalin 作用于 1 个分子靶点:

CACNA2D1calcium voltage-gated channel auxiliary subunit alpha2delta 1 (LINC01112, CACNA2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

pregabalin 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersDiabetic neuropathy✓ Approved
Nervous system disordersPost herpetic neuralgia✓ Approved

相关研究文献

PubMedRehabilitacion2026-11-18

[Clinical profile and management of patients with neuropathic pain treated with pregabalin in rehabilitation clinics in Spain: the PRELURE cross-sectional survey].

de Miguel Benadiba C C, Ambrós Helena Bascuñana HB

To describe the clinical profile and management of patients with neuropathic pain referred for the first time to Physical Medicine and Rehabilitation clinics in Spain, as well as the use of pregabalin. A descriptive, nationwide survey based on aggregated data obtained through an online questionnaire. Each participant provided information on their last 6 patients with neuropathic pain referred for the first time and prescribed pregabalin at the consultation. A total of 124 specialists participated. Among their patients, chronic pain predominated (100.0%; Q1-Q3: 66.7-100.0), with a median duration of 8 months, as did mixed neuropathic-nociceptive pain (66.7%; Q1-Q3: 33.3-100.0). Baseline pain intensity (0-10) was high, with a mean score of 7.2 (SD 1.2) in women and 6.8 (SD 1.0) in men. Functional impairment, sleep and mood impairment were frequent. Before referral, pregabalin use was limited, with a mean initial dose of 104.9 (SD 65.7) mg/day in women and 130.5 (SD 110.8) mg/day in men. Following the consultation, the reported mean dose was 147.4 (SD 112.2) and 148.8 (SD 92.4) mg/day, respectively. Based on the physicians' retrospective estimates, at three months after treatmen adjustment, they perceived a reduction in the mean proportion of patients experiencing severe pain to 5.9% in women and 4.8% in men. Patients referred to Rehabilitation and treated with pregabalin present a high symptomatic and functional burden. Lower doses were observed before referral. After the consultation, treatment was adjusted and physicians perceived a reduction in patients with severe pain at three months.

PMID 43051522
阅读全文 →
PubMedFrontiers in human neuroscience2026-11-18

A thalamus-centered network model of restless legs syndrome: an integrative hypothesis illustrated by three clinical phenotypes.

Vághy Beatrix B, Komoly Sámuel S, Várbíró Szabolcs S

Restless legs syndrome (RLS) is a clinically heterogeneous sensorimotor disorder whose pathophysiology reflects interacting biological mechanisms rather than a single causal pathway. Established influences-including brain iron biology, dopaminergic regulation, glutamatergic and GABAergic balance, adenosinergic inhibition, and abnormal afferent processing-have typically been studied in isolation, leaving their systems-level relationships insufficiently integrated. To motivate a network-based interpretation, we present three illustrative clinical phenotypes: dopamine-agonist augmentation, sensory-predominant RLS with inadequate response to pregabalin, and persistent symptoms despite partial correction of peripheral iron deficiency. These cases highlight how distinct upstream contexts can converge on similar sensory and sleep-physiological endpoints. Human neuroimaging and neurochemical studies provide convergent evidence for thalamic involvement in RLS, including altered thalamic connectivity, differences in thalamic nuclei and network organization, and increased thalamic glutamate/glutamine signal associated with disturbed sleep. Because the thalamus integrates sensory gating, motor modulation, arousal regulation, and sleep-wake stability, it represents a plausible convergence hub for upstream biological influences. We therefore propose a thalamus-centered convergence model in which iron deficiency, dopaminergic instability, glutamatergic hyperresponsiveness, reduced adenosinergic inhibition, altered GABAergic modulation, and abnormal afferent processing interact to increase the susceptibility of thalamo-cortical networks to sensory and arousal instability. The model does not replace established frameworks; instead, it organizes them within a unified, testable network architecture. We outline six falsifiable predictions for multimodal imaging, sleep microstructure, sensory physiology, and treatment-response studies, providing a structured basis for future mechanistic investigation of RLS.

PMID 43048388
阅读全文 →
PubMedEpilepsia2026-11-18

Validation of drug-resistant epilepsy identification algorithms in US Veterans across diverse care settings.

Haneef Zulfi Z, Nagabhirava Rohan S RS, Hildebrand Andrea D AD, Zhou Richard R et al.

Early recognition of drug-resistant epilepsy (DRE) is critical for timely referral to comprehensive epilepsy centers (CECs). Our prior pilot study in the Veterans Health Administration (VHA) demonstrated the feasibility of an algorithm-based approach to identify DRE within selected CECs. In this study, we validated and refined these algorithms in a broader, national cohort, including CEC and non-CEC care, to optimize algorithms for different care settings. We conducted a multicenter, retrospective study of randomly sampled veterans with epilepsy on ≥2 antiseizure medications (ASMs) from 1999 to 2024. Chart review by 26 epilepsy providers rated DRE status. Ninety-six candidate algorithms using combinations of six criteria-number of ASMs, treatment duration, dose thresholds, pregabalin exclusion, intractable International Classification of Diseases (ICD) codes, and electroencephalography (EEG)/magnetic resonance imaging (MRI) utilization-were evaluated. Performance for DRE classification was evaluated among all veterans, and separately for CEC or non-CEC care. Among 970 veterans on ≥2 lifetime ASMs, 518 (53.4%) were rated as DRE, 363 (37.4%) as non-DRE, and 89 (9.2%) as undetermined. Veterans with DRE were younger (mean age = 68.9 vs. 72.0 years) and more frequently had at least one intractable ICD code (46.1% vs. 18.2%), EEG (77.8% vs. 66.7%), or MRI (78.0% vs. 65.8%) compared with non-DRE (all p-values <.001). Among all veterans, the best overall algorithm (area under the curve [AUC] = .701) identified DRE as either (1) exposure to 3+ ASMs or (2) exposure to two ASMs for at least 1 year, with the requirement of past EEG/MRI and intractable ICD code documentation. This algorithm was also highly effective among veterans who received CEC (AUC = .756) or only non-CEC care (AUC = .678). This national validation study confirms that medication-based algorithms can identify DRE within VHA administrative data across care settings (CECs and non-CECs). This supports the implementation of a standardized DRE definition for quality improvement, surveillance, and referral optimization within the VHA.

PMID 43049542
阅读全文 →
PubMedGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology2026-11-18

Non-hormonal management of menopause symptoms-the statement of the European Society of Gynecology.

Castelo-Branco Camil C, Kiesel Ludwig L, Yoldemir Tevfik T, Chabbert-Buffet Nathalie N et al.

Menopausal symptoms, particularly vasomotor symptoms (VMS), sleep disturbances, mood disorders, and genitourinary syndrome of menopause (GSM), affect a substantial proportion of women and may significantly impair the quality of life. Although menopausal hormone therapy (MHT) remains the most effective treatment, many women have contraindications to hormonal treatment or prefer non-hormonal options. To review and provide evidence-based recommendations on current non-hormonal interventions for the management of menopausal symptoms. The European Society of Gynecology convened an expert panel that performed a comprehensive literature review using MEDLINE and EMBASE. Clinical guidelines, systematic reviews, meta-analyzes, randomized controlled trials, and relevant primary studies evaluating non-hormonal interventions for menopausal symptoms were identified, critically appraised, and synthesized through a structured consensus process. Lifestyle modification, including healthy diet, regular physical activity, weight control, sleep hygiene, and behavioral interventions, forms the foundation of menopausal care. Among pharmacological therapies, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, gabapentin, clonidine, oxybutynin, and pregabalin demonstrate varying degrees of efficacy for VMS. Neurokinin receptor antagonists, particularly fezolinetant and elinzanetant, represent the most effective evidence-based non-hormonal pharmacologic therapies currently available. Cognitive behavioral therapy and clinical hypnosis effectively reduce VMS-related distress and improve sleep and quality of life. Evidence for complementary approaches such as mindfulness, yoga, acupuncture, acupressure, reflexology, phytoestrogens, S-equol, DT56a, purified pollen extracts, and black cohosh ranges from moderate to limited. For GSM, lubricants, moisturizers, hyaluronic acid preparations, and pelvic floor muscle training provide symptomatic benefit, whereas current evidence does not support routine use of vaginal laser therapy. Non-hormonal therapies provide effective and individualized treatment options for menopausal symptoms, particularly for women who are unable or unwilling to use MHT. Neurokinin receptor antagonists, selected pharmacologic agents, psychological interventions, and targeted GSM therapies represent the strongest evidence-based approaches currently available. The choice of treatment should consider symptom profile, contraindications, adverse effects, regulatory approval, and patient preferences.

PMID 43049482
阅读全文 →
PubMedInternational journal of spine surgery2026-11-18

Gabapentinoid Exposure and Persistent Postoperative Opioid Use After Lumbar Spinal Fusion: A Systematic Review and Meta-Analysis.

Alves Matheus Loiola Magalhães MLM, da Silva Moura Costa Antônio Olímpio AO, Benites Vinicius de Meldau VM, Gandolfi Ana Camila de Castro ACC et al.

Gabapentinoids are used in multimodal analgesia, but their association with persistent opioid use after lumbar fusion remains uncertain. This systematic review and meta-analysis compared adults exposed to gabapentin or pregabalin with unexposed patients. The primary outcome was persistent opioid use or prescription. Inpatient opioid consumption, postoperative pain, and disability were assessed as secondary outcomes. The PubMed, Embase, and the Cochrane Library databases were searched through 30 August 2026. Comparative studies of adults undergoing spinal fusion were eligible if they evaluated gabapentinoid exposure vs no exposure under usual care or a comparable opioid-based regimen. Two reviewers independently selected studies, extracted data, and assessed risk of bias using ROBINS-I. Cohorts with a high probability of overlap were not included together in the same pooled estimates. Random-effects models estimated risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). Six retrospective cohort studies involving patients undergoing lumbar fusion were included. Gabapentinoid exposure was not significantly associated with persistent opioid use or prescription at the longest compatible follow-up (RR, 1.03; 95% CI, 0.89-1.19; P = 0.67) or at 3-6 months (RR, 1.03; 95% CI, 0.81-1.32; P = 0.73). There were also no significant differences in inpatient opioid consumption (MD, 43.13 morphine milligram equivalents; 95% CI, -9.72 to 95.99; P = 0.07) or change in the Oswestry Disability Index at 12 months (MD, 2.73 points; 95% CI, -8.54 to 14.00; P = 0.41). Findings for persistent opioid use were consistent in temporal and publication-level sensitivity analyses. Observational evidence showed no statistically significant association between gabapentinoid exposure and persistent opioid use or prescription after lumbar fusion. There were also no significant differences in inpatient opioid consumption or 12-month changes in back pain, leg pain, or disability scores. Gabapentinoid use should remain individualized; these findings do not establish a benefit in reducing long-term opioid use after lumbar fusion. PROSPERO CRD420261493895.

PMID 43052000
阅读全文 →
PubMedCureus2026-11-15

Persistent Unilateral Facial Inflammation Associated With a Calcium Hydroxylapatite-Compatible Foreign-Body Reaction: A Case Report.

Olivares Macarena M, Abaroa Nicole N, Mercado Victor V

Calcium hydroxylapatite (CaHA) is a widely used biostimulatory dermal filler, although persistent inflammatory complications may occur. We report the case of a 23-year-old woman who developed progressive unilateral inflammation of the left midface and lower face several weeks after CaHA injection. Symptoms persisted for approximately two years despite previous diagnoses and treatments. At presentation, she had facial asymmetry, persistent edema, induration, severe pain, and mechanical allodynia. High-resolution ultrasound showed diffuse abnormalities of the subcutaneous adipose tissue, consistent with edema and inflammatory involvement. An incisional biopsy demonstrated fibrous tissue containing exogenous spherules compatible with CaHA and a foreign-body granulomatous reaction. The patient received a multimodal regimen comprising oral and intralesional corticosteroids, pregabalin, collagenase, and lipase. Clinical and ultrasound improvement was observed during ongoing treatment, with residual tissue abnormalities at the latest follow-up. Ultrasound findings did not establish histological resolution of fibrosis. Because interventions were administered sequentially and in combination, improvement cannot be attributed to any single treatment. This case illustrates the complementary roles of clinical assessment, ultrasound, and histopathology in evaluating persistent inflammation after CaHA injection.

PMID 43034652
阅读全文 →

注册免费账户还可查看另外 5413 篇文献

免费注册查看全部文献 →

了解更多pregabalin